Publication:
Renal dysfunction during tenofovir use in a regional cohort of HIV-infected individuals in the Asia-Pacific

dc.contributor.authorJunko Tanumaen_US
dc.contributor.authorAwachana Jiamsakulen_US
dc.contributor.authorAbhimanyu Makaneen_US
dc.contributor.authorAnchalee Avihingsanonen_US
dc.contributor.authorOon Tek Ngen_US
dc.contributor.authorSasisopin Kiertiburanakulen_US
dc.contributor.authorRomanee Chaiwarithen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorKinh Van Nguyenen_US
dc.contributor.authorThuy Thanh Phamen_US
dc.contributor.authorMan Po Leeen_US
dc.contributor.authorRossana Ditangcoen_US
dc.contributor.authorTuti Parwati Meratien_US
dc.contributor.authorJun Yong Choien_US
dc.contributor.authorWing Wai Wongen_US
dc.contributor.authorAdeeba Kamarulzamanen_US
dc.contributor.authorEvy Yunihastutien_US
dc.contributor.authorBenedict Lh Simen_US
dc.contributor.authorWinai Ratanasuwanen_US
dc.contributor.authorPacharee Kantipongen_US
dc.contributor.authorFujie Zhangen_US
dc.contributor.authorMahiran Mustafaen_US
dc.contributor.authorVonthanak Saphonnen_US
dc.contributor.authorSanjay Pujarien_US
dc.contributor.authorAnnette H. Sohnen_US
dc.contributor.authorC. V. Meanen_US
dc.contributor.authorV. Saphonnen_US
dc.contributor.authorK. Vohithen_US
dc.contributor.authorF. J. Zhangen_US
dc.contributor.authorH. X. Zhaoen_US
dc.contributor.authorN. Hanen_US
dc.contributor.authorP. C.K. Lien_US
dc.contributor.authorW. Lamen_US
dc.contributor.authorY. T. Chanen_US
dc.contributor.authorK. H. Wongen_US
dc.contributor.authorS. Saghayamen_US
dc.contributor.authorC. Ezhilarasien_US
dc.contributor.authorK. Joshien_US
dc.contributor.authorD. N. Wirawanen_US
dc.contributor.authorF. Yulianaen_US
dc.contributor.authorD. Imranen_US
dc.contributor.authorA. Widhanien_US
dc.contributor.authorS. Okaen_US
dc.contributor.authorT. Nishijimaen_US
dc.contributor.authorS. Naen_US
dc.contributor.authorJ. M. Kimen_US
dc.contributor.authorY. M. Ganien_US
dc.contributor.authorR. Daviden_US
dc.contributor.authorS. F.Syed Omaren_US
dc.contributor.authorS. Ponnampalavanaren_US
dc.contributor.authorI. Azwaen_US
dc.contributor.authorN. Hudaen_US
dc.contributor.authorL. Y. Ongen_US
dc.contributor.authorE. Uyen_US
dc.contributor.authorR. Bantiqueen_US
dc.contributor.authorW. W. Kuen_US
dc.contributor.authorP. C. Wuen_US
dc.contributor.authorP. L. Limen_US
dc.contributor.authorL. S. Leeen_US
dc.contributor.authorP. S. Ohnmaren_US
dc.contributor.authorP. Phanuphaken_US
dc.contributor.authorK. Ruxrungthamen_US
dc.contributor.authorP. Chusuten_US
dc.contributor.authorS. Sirivichayakulen_US
dc.contributor.authorS. Sungkanuparphen_US
dc.contributor.authorL. Chumlaen_US
dc.contributor.authorN. Sanmeemaen_US
dc.contributor.authorR. Chaiwarithen_US
dc.contributor.authorT. Sirisanthanaen_US
dc.contributor.authorW. Kotarathititumen_US
dc.contributor.authorJ. Praparattanapanen_US
dc.contributor.authorP. Kantipongen_US
dc.contributor.authorP. Kambuaen_US
dc.contributor.authorR. Sriondeeen_US
dc.contributor.authorV. H. Buien_US
dc.contributor.authorT. T. Caoen_US
dc.contributor.authorD. D. Cuongen_US
dc.contributor.authorH. L. Haen_US
dc.contributor.authorN. Durieren_US
dc.contributor.authorB. Petersenen_US
dc.contributor.authorT. Singtorojen_US
dc.contributor.authorD. A. Cooperen_US
dc.contributor.authorM. G. Lawen_US
dc.contributor.authorD. C. Boettigeren_US
dc.contributor.otherNational Center for Global Health and Medicineen_US
dc.contributor.otherUniversity of New South Wales (UNSW) Australiaen_US
dc.contributor.otherInstitute of Infectious Diseasesen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherVHS Medical Centre Indiaen_US
dc.contributor.otherNational Hospital of Tropical Diseasesen_US
dc.contributor.otherBach Mai Hospitalen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherGokilaen_US
dc.contributor.otherUniversitas Udayanaen_US
dc.contributor.otherYonsei Universityen_US
dc.contributor.otherVeterans General Hospital-Taipeien_US
dc.contributor.otherUniversity of Malaya Medical Centreen_US
dc.contributor.otherUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
dc.contributor.otherHospital Sungai Bulohen_US
dc.contributor.otherChiangrai Prachanukroh Hospitalen_US
dc.contributor.otherBeijing Ditan Hospitalen_US
dc.contributor.otherHospital Raja Perempuan Zainab IIen_US
dc.contributor.otherUniversity of Health Sciencesen_US
dc.contributor.otheramfAR - The Foundation for AIDS Researchen_US
dc.contributor.otherNational Center for HIV/AIDSen_US
dc.contributor.otherIntegrated Treatment Centreen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherNational Hospital for Tropical Diseasesen_US
dc.date.accessioned2018-12-11T01:57:36Z
dc.date.accessioned2019-03-14T08:04:19Z
dc.date.available2018-12-11T01:57:36Z
dc.date.available2019-03-14T08:04:19Z
dc.date.issued2016-08-01en_US
dc.description.abstract© 2016 Tanuma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background: In resource-limited settings, routine monitoring of renal function during antiretroviral therapy (ART) has not been recommended. However, concerns for tenofovir disoproxil fumarate (TDF)-related nephrotoxicity persist with increased use. Methods: We investigated serum creatinine (S-Cr) monitoring rates before and during ART and the incidence and prevalence of renal dysfunction after starting TDF by using data from a regional cohort of HIV-infected individuals in the Asia-Pacific. Time to renal dysfunction was defined as time from TDF initiation to the decline in estimated glomerular filtration rate (eGFR) to <60 ml/min/1.73m2 with >30% reduction from baseline using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation or the decision to stop TDF for reported TDF-nephrotoxicity. Predictors of S-Cr monitoring rates were assessed by Poisson regression and risk factors for developing renal dysfunction were assessed by Cox regression. Results: Among 2,425 patients who received TDF, S-Cr monitoring rates increased from 1.01 to 1.84 per person per year after starting TDF (incidence rate ratio 1.68, 95%CI 1.62-1.74, p <0.001). Renal dysfunction on TDF occurred in 103 patients over 5,368 person-years of TDF use (4.2%; incidence 1.75 per 100 person-years). Risk factors for developing renal dysfunction included older age (>50 vs. ≤30, hazard ratio [HR] 5.39, 95%CI 2.52-11.50, p <0.001; and using PI-based regimen (HR 1.93, 95%CI 1.22-3.07, p = 0.005). Having an eGFR prior to TDF (pre-TDF eGFR) of ≥60 ml/min/1.73m2 showed a protective effect (HR 0.38, 95%CI, 0.17-0.85, p = 0.018). Conclusions: Renal dysfunction on commencing TDF use was not common, however, older age, lower baseline eGFR and PI-based ART were associated with higher risk of renal dysfunction during TDF use in adult HIV-infected individuals in the Asia-Pacific region.en_US
dc.identifier.citationPLoS ONE. Vol.11, No.8 (2016)en_US
dc.identifier.doi10.1371/journal.pone.0161562en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-84990036805en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/43243
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84990036805&origin=inwarden_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleRenal dysfunction during tenofovir use in a regional cohort of HIV-infected individuals in the Asia-Pacificen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84990036805&origin=inwarden_US

Files

Collections